News Feature | Published:

Biogenerics standoff

Nature Biotechnology volume 22, pages 13431346 (2004) | Download Citation

Subjects

Healthcare costs are out of control. Generic biotech products could ease the pain. What's holding things up? Stephan Herrera investigates.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    SMI out of pocket expenses as percentage of illustrative Social Security benefit.

  2. 2.

    GM health care bill tops $60 billion. Detroit News March 11 (2004), p. 1.

  3. 3.

    Carmakers in for a long haul in paying for retiree health care. New York Times September 14 (2004), p. 1.

  4. 4.

    Kaiser Family Foundation. Trends and indicators in the changing health care marketplace, 2004 Update. April 2004.

  5. 5.

    Lessons from Eprex for biogeneric firms, Nat. Biotech. 21, 956–957 (2003).

  6. 6.

    How drug giant keeps monopoly on 60-year old pill. Wall Street Journal September 9 (2004), p. A1.

  7. 7.

    Biogenerics, a difficult birth? IMS Health, Online newsletter, May 18, 2004.

  8. 8.

    USFDA/CDER Report to the Nation: 1999, International Activities. (FDA/Center for Drug Evaluation and Research, Washington, DC, 2001).

Download references

Author information

Affiliations

  1. New York

    • Stephan Herrera

Authors

  1. Search for Stephan Herrera in:

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt1104-1343

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing